Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II Non–Small Cell Lung Cancer: The Mayo Clinic Experience

To examine disease control and survival after stereotactic body radiotherapy (SBRT) for medically inoperable, early-stage non–small cell lung cancer (NSCLC) and determine associations of pretreatment 18F-fluorodeoxyglucose–positron emission tomography (FDG-PET) maximum standardized uptake values (SU...

Full description

Saved in:

Bibliographic Details
Published in:	Mayo Clinic proceedings. Innovations, quality & outcomes Vol. 2; no. 1; pp. 40 - 48
Main Authors:	Hobbs, Corey J., Ko, Stephen J., Paryani, Nitesh N., Accurso, Joseph M., Olivier, Kenneth R., Garces, Yolanda I., Park, Sean S., Hallemeier, Christopher L., Schild, Steven E., Vora, Sujay A., Ashman, Jonathan B., Rule, William G., Bowers, Johnny R., Heckman, Michael G., Diehl, Nancy N., Miller, Robert C.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Inc 01-03-2018 Elsevier
Subjects:	Original BED FDG-PET NSCLC OS SUVmax HR ITV DFS CT LC SBRT EBUS RTOG PET FDG-PET, 18F-fludeoxyglucose–positron emission tomography PET, positron emission tomography LC, local control HR, hazard ratio SUVmax, maximum standardized uptake value BED, biologically effective dose CT, computed tomography ITV, internal target volume SBRT, stereotactic body radiotherapy OS, overall survival RTOG, Radiation Therapy Oncology Group EBUS, endobronchial ultrasonography NSCLC, non–small cell lung cancer DFS, disease-free survival
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	To examine disease control and survival after stereotactic body radiotherapy (SBRT) for medically inoperable, early-stage non–small cell lung cancer (NSCLC) and determine associations of pretreatment 18F-fluorodeoxyglucose–positron emission tomography (FDG-PET) maximum standardized uptake values (SUVmax), biologically effective dose, and mediastinal staging with disease control and survival outcomes. We retrospectively reviewed the cases of consecutive patients with FDG-PET–staged, medically inoperable NSCLC treated with SBRT at our institution between January 1, 2008, and August 4, 2014. Cumulative incidences of recurrence were estimated, accounting for the competing risk of death. Associations of SUVmax, biologically effective dose, and mediastinal staging with outcomes were evaluated using Cox proportional hazards regression models. Among 282 patients, 2-year cumulative incidences of recurrence were 4.9% (95% CI, 2.6%-8.3%) for local, 9.8% (95% CI, 6.3%-14.2%) for nodal, 10.8% (95% CI, 7.0%-15.5%) for ipsilateral lung, 6.0% (3.3%-9.8%) for contralateral lung, 9.7% (95% CI, 6.3%-14.0%) for distant recurrence, and 26.1% (95% CI, 20.4%-32.0%) for any recurrence. The 2-year overall survival was 70.4% (95% CI, 64.5%-76.8%), and the 2-year disease-free survival was 51.2% (95% CI, 44.9%-58.5%). Risk of any recurrence was significantly higher for patients with higher SUVmax (hazard ratio [per each doubling], 1.29 [95% CI, 1.05-1.59]; P=.02). A similar association with SUVmax was observed when considering the composite outcome of any recurrence or death (hazard ratio, 1.23 [95% CI, 1.05-1.44]; P=.01). The SUVmax was not significantly associated with other outcomes (P≥0.69). Two-year cumulative incidences of local recurrence for patients receiving 48 Gy in 4 fractions, 54 Gy in 3 fractions, or 50 Gy in 5 fractions were 1.7% (95% CI, 0.3%-5.6%), 3.7% (95% CI, 0.7%-11.4%), and 15.3% (95% CI, 5.9%-28.9%), respectively (P=.02); this difference was independent of lesion size (P=.02). Disease control was excellent for patients who received SBRT for early-stage NSCLC, and this series represents the largest single-institution experience from the United States on SBRT for early-stage inoperable NSCLC. Higher pretreatment FDG-PET SUVmax was associated with increased risk of any recurrence, and the 50 Gy in 5 fractions dose prescription was associated with increased risk of local recurrence.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	2542-4548 2542-4548
DOI:	10.1016/j.mayocpiqo.2017.11.001